Molecular Origami: Start-Ups Tackle Protein Folding
This article was originally published in Start Up
Executive Summary
Start-ups are developing novel therapeutics that work by shepherding faulty proteins into their normal conformations. The risky approach, if successful, could dramatically increase the pharmaceutical arsenal. Drug companies remain skeptical, prefering to wait for clinical validation of the existing compounds before inking big deals.